Cardiva Medical

What Cardiva Medical does

Cardiva Medical is a privately held medical device company founded in 2002 and headquartered in Sunnyvale, California, that develops and commercializes vascular closure technology designed to help the body heal after catheter-based vascular access procedures. The company's core product platform centers on closure devices used in interventional cardiology, electrophysiology, and endovascular surgery—procedural settings where reliable hemostasis at the arterial or venous access site is essential. The technology is designed to facilitate natural healing, distinguishing it from purely mechanical closure approaches; the platform supports variants including large-bore and same-day-discharge workflows, as evidenced by VASCADE MVP and Same Day Discharge product extensions visible through the Haemonetics Hospital Solutions commercial channel.

The company's commercial footprint spans the United States and, through partner distribution channels, extends internationally across Canada, Europe (France, Germany, Italy, Spain, UK), Japan, China, and additional markets. Cardiva operates a commercial-stage business with 101-250 employees, structured around functional leadership in R&D, regulatory and clinical affairs, strategy, and finance. The company has raised approximately $181M in disclosed equity funding across 13 rounds from 2003 through 2020, with a concentrated syndicate of healthcare-specialist investors including Evidity Health Capital, PTV Healthcare Capital, Triventures, Galen Partners, and Essex Woodlands Healthcare Partners.

Cardiva's revenue mechanics are anchored in unit-based medical device sales to hospitals and integrated delivery networks, with revenue visibility tied to procedure volumes in catheterization labs and surgical suites. Distribution is exercised both directly and through partnerships—most notably through Haemonetics' Hospital Solutions commercial channel, which positions VASCADE alongside other interventional technologies. The company's investor profile, sustained funding cadence, and product portfolio extensions indicate an established commercial organization pursuing both organic growth and clinical workflow expansion in the vascular access management market.

Name

Cardiva Medical

Website

https://cardivamedical.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

Cardiva Medical is a privately held Sunnyvale-based medical device company founded in 2002 that develops and commercializes vascular closure technology to help the body heal after catheter-based procedures, serving interventional cardiology, electrophysiology, and vascular surgery markets in the U.S. and internationally.

Ownership category

akta.pro rank

Product category

Vascular Closure Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

akta.pro secondary industries

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)

Keywords

• Vascular closure devices
• Femoral closure systems
• Hemostasis management
• Interventional cardiology devices
• Cath lab access closure

Headquarters

HQ city

Sunnyvale

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Core offering

Cardiva Medical designs, develops, and commercializes vascular closure technology intended to help the body heal after catheterization procedures. The company's core products are closure devices used to seal femoral arterial and venous access sites in interventional cardiology, electrophysiology, and endovascular procedures. The platform emphasizes extravascular, bioresorbable designs that avoid leaving intra-arterial components behind, supporting earlier ambulation and same-day discharge pathways.

Differentiator

Problem solved

Functional benefit

Products and services

• VASCADE Vascular Closure System

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Abbott Vascular: Abbott's vascular division sells the Perclose and StarClose closure device lines, dominating the interventional cardiology and endovascular closure market. Comparable to Cardiva as a direct product competitor but with a vastly broader cardiovascular portfolio and global salesforce.
• Terumo (Terumo Medical): Terumo manufactures the Angio-Seal vascular closure device, one of the most widely used closure platforms globally. Direct product overlap with Cardiva in vascular closure for interventional and endovascular procedures.
• Cardinal Health: Cardinal Health distributes and has historically commercialized closure devices (formerly AccessClosure portfolio) through its medical segment. Operates at much larger scale than Cardiva with broader med-surg distribution channels touching the same hospital call points.
• Cook Medical: Cook Medical manufactures a broad range of vascular access and closure devices for interventional procedures. Larger incumbent with overlapping product categories in vascular access but a much broader overall portfolio than Cardiva.

Direct peers

• Teleflex: Teleflex offers the Mynx and VasoSeal closure device families focused on vascular closure for catheterization procedures. Closely comparable to Cardiva in product focus, customer base (interventional cardiologists and radiologists), and regulatory pathway.
• Haemonetics: Haemonetics acquired Cardiva's VASCADE platform and now sells VASCADE/VASCADE MVP directly through its Interventional Technologies business. Operates the same product line as Cardiva and represents both the strategic acquirer and now a direct go-to-market vehicle.
• Merit Medical Systems: Merit Medical sells vascular closure and access products (e.g., Prelude, Safeguard) targeting interventional radiology and cardiology. Comparable mid-cap medical device peer with overlapping closure/access product portfolio.

Emerging players

• Vivasure Medical: Vivasure is developing next-generation bioabsorbable closure devices for large-bore vascular access procedures. Comparable to Cardiva in the bioresorbable approach to vascular closure but focused on a higher-acuity, large-bore segment.
• InSeal Medical: InSeal is an early-stage developer of vascular closure devices using a bioresorbable sealing patch concept. Direct emerging-stage competitor with overlapping vascular closure value proposition.
• Essential Medical: Essential Medical focused on large-bore vascular closure with the MANTA device before being acquired by Teleflex. Relevant as a historical emerging player in the same closure category as Cardiva.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/cardivamedical
• LinkedInlinkedin.com/company/cardiva-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds13 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cardiva Medical